LIMFOMA IZ KLETOK MANTII V POZhILOM VOZRASTE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mantle cell lymphoma (MCL) is considered as relatively rare variant of B-cell tumors with specific cytogenetic and immunophenotypic characteristics. Median patient’s age is 65 years. Currently, the only method of adequate treatment of disease is allogeneic transplantation, the possibility of which is primarily determined by the patient's age and comorbidity. Elderly age and comorbidities may preclude the most effective treatment programs, including high-dose cytarabine followed by high-dose chemotherapy and autologous hemopoietic stem cell transplantation. All this necessitates the development of individualized approaches to the treatment of elderly patients with MCL. The international randomized study shows that use of R-CHOP regimen (rituximab, doxorubicin, vincristine, cyclophosphamide, prednisolone) for the elderly patients with primary MCL followed by maintenance therapy with rituximab allows to achieve satisfactory progression-free survival. In some cases, however, the presence of concomitant diseases interferes with the use of R-CHOP regimen. Program with bendamustine in combination with rituximab can be considered as alternative a as less toxic and comparable in efficacy. Relapses of the disease are observed in absolute majority of patients with MCL. This publication presents a clinical case of successful use of bendamustine in the treatment of relapse of MCL in patient aged 80.

Full Text

Restricted Access

About the authors

N. A Falaleeva

Email: falaleeva-n@mail.ru

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11): 3909-18.
  2. Doorduijn J.K., Kluin-Nelemans H.C. Management of mantle cell lymphoma in the elderly patient. Clin. Interv. Aging. 2013; 8: 1229-36.
  3. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008.
  4. Fu K., Weisenburger D.D., Greiner T.C., et al. Cyclin Di-negative mantle cell lymphoma a clinicopathologic study based on gene expression profiling. Blood. 2005; 106(13): 4315-21.
  5. Dreyling M., Hiddemann W. Current treatment standards and emerging in mantle cell lymphoma. ASH Education Book. 2009: 1542-51.
  6. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J. Clin. Oncol. 2009; 27(4): 511-18.
  7. Howard O.M., Gribben J.G., Neuberg D.S., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 2002; 20(5): 1288-94.
  8. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 2005; 23(9): 1984-92.
  9. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2007; 99(9): 706-14.
  10. Griffiths R., Mikhael J., Gleeson M., Danese M., Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011; 118(18): 4808-16.
  11. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/ cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantlecell lymphoma. J. Clin. Oncol. 1998; 16(12): 3803-809.
  12. van't Veer M.B., de Jong D., MacKenzie M., et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br. J. Haematol. 2009; 144(4): 524-30.
  13. Geisler C.H., Kolstad A., Laurell A., et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stemcell support: still very long survival but late relapses do occur. Br. J. Haematol. 2012; 158(3): 355-62.
  14. Delarue R., Haioun C., Ribrag V., et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013; 121(1): 48-53.
  15. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br. J. Haematol. 2003; 120(5): 793-800.
  16. Peterlin P., Leux C., Gastinne T., et al. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation. 2012; 94(3): 295-301.
  17. Dreyling M., Hoster E., Hermine O., et al. European Mantle Cell Lymphoma Network: an update on current first line trials [abstract]. Ann. Oncol. 2008; 19: 300.
  18. Pott C., Hoster E., Delfau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010; 115(16): 3215-23.
  19. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade. Lymphoma Study Group (GLSG). J. Clin. Oncol. 2005; 23(9): 1984-92.
  20. Kluin-Nelemans H.C., Hoster E., Hermine O., et al. Treatment of older patients with mantle-cell lymphoma. N. Engl. J. Med. 2012; 367(6): 520-31.
  21. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873): 1203-10.
  22. Coleman M., Martin P., Ruan I. et al. Prednisone, etoposide, procarbazine, cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic multidrug therapy. Cancer 2008: 112; 2228-32.
  23. Bauwens D., Maerevoet M., Michaux L., et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br. J. Haematol. 2005; 131(3): 338-40.
  24. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. 2005; 23(4): 705-11.
  25. Rosenbluth B.D., Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int. J. Radiat. Oncol. Biol. Phys. 2006; 65(4): 1185-91.
  26. Cheson B.D., Friedberg J.W., Kahl B.S., et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk. 2010; 10(6): 452-57.
  27. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23(15): 3383-89.
  28. Weide R., Hess G., Koppler H., et al. High antilymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma. 2007; 48(7): 1299-1306.
  29. Thomas D.W., Owen R.G., Johnson S.A., et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk. Lymphoma. 2005; 46(4): 549-52.
  30. Visco C., Finotto S., Zambello R., et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J. Clin. Oncol. 2013; 31(11): 1442-49.
  31. Inwards D.J., Fishkin P.A., Hillman D.W., et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladrib-ine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008; 113(1): 108-16.
  32. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006; 24(30): 4867-74.
  33. O'Connor O.A., Moskowitz C., Portlock C., et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br. J. Haematol. 2009; 145(1): 34-9.
  34. Weigert O., Weidmann E., Mueck R., et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - longterm results of a multicenter observation study. Leuk. Lymphoma. 2009; 50(5): 716-22.
  35. Witzig T.E., Vose J.M., Zinzani P.L., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann. Oncol. 2011; 22(7): 1622-27.
  36. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 2009; 145(3): 344-49.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies